Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders

Hepatology Research

Volumn 42, Issue 4, 2012, Pages 340-348

  Yamasaki, Takahiro ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced hepatocellular carcinoma; Branched chain amino acid; Deferoxamine; Hepatic arterial infusion chemotherapy; Iron chelator; Nutritional therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA TOCOPHEROL; CISPLATIN; DEFEROXAMINE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; PEGINTERFERON ALPHA; RETINOL; SORAFENIB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CHOLESTEROL BLOOD LEVEL; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENERGY METABOLISM; HUMAN; IMMUNOCOMPETENT CELL; INSULIN RESISTANCE; INTERSTITIAL PNEUMONIA; IRON METABOLISM; KIDNEY DYSFUNCTION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; LOW DRUG DOSE; NATURAL KILLER CELL; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; REVIEW; TREATMENT RESPONSE;

EID: 84858840146     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00938.x     Document Type: Review

References (65)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Bruix J, Sherman M, Llovet JM etal. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-30.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
4. Sangiovanni A, Del Ninno E, Fasani P etal. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-14.
5. Han KH, Kim JK. Liver cancer in Korea. Hepatol Res 2007; 37 (Suppl 2): S106-9.
6. El-Serag HB, Siegel AB, Davila JA etal. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44: 458-66.
7. th follow-up survey of primary liver cancer in Japan. Hepatol Res 2010; 40: 1043-59.
8. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
9. Llovet JM, Di Bisceglie AM, Bruix J etal. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 1000: 698-711.
10. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-85.
11. Ota H, Nagano H, Sakon M etal. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 557-64.
12. Obi S, Yoshida H, Toune R etal. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-7.
13. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 1890-6.
14. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-95.
15. Nagano H. Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 2010; 78 (Suppl 1): 142-7.
16. Nagano H, Wada H, Kobayashi S etal. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology 2011; 80: 63-9.
17. Yamasaki T, Kimura T, Kurokawa F etal. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40: 70-8.
18. Takaki-Hamabe S, Yamasaki T, Saeki I etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res 2009; 39: 223-30.
19. Nagamatsu H, Hiraki M, Mizukami N etal. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracila for hepatocellular carcinoma with portal vein tumor thrombosis. Aliment Pharmacol Ther 2010; 32: 543-50.
20. Kim BK, Park JY, Choi HJ etal. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 659-67.
21. Urayama N, Yamasaki T, Harima Y etal. Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: analysis of 114 cases. Kanzo (in Japanese) 2011; 52: 499-60.
22. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
23. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
24. Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J Hepatol 1994; 21: 317-25.
25. Lautz HU, Selberg O, Korber J, Burger M, Muller MJ. Protein-calorie malnutrition in liver cirrhosis. Clin Investig 1992; 70: 478-86.
26. Tajika M, Kato M, Mohri H etal. Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition 2002; 18: 229-34.
27. Okamoto M, Sakaida I, Tsuchiya M, Suzuki C, Okita K. Effect of late evening snack on the blood glucose level and energy metabolism in patients with liver cirrhosis. Hepatol Res 2003; 27: 45-50.
28. Sakaida I, Tsuchiya M, Okamoto M, Okita K. Late evening snack and the change of blood glucose level in patients with liver cirrhosis. Hepatol Res 2004; 30S: 67-72.
29. Tsuchiya M, Sakaida I, Okamoto M, Okita K. The effect of a late evening snack in patients with liver cirrhosis. Hepatol Res 2005; 31: 95-103.
30. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and eternal nutrition in adult and pediatric patients. JPEN 2002; 26: 65SA-8SA.
31. Plauth M, Merli M, Konrup J, Weimann A, Ferenci P, Müller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. Clin Nutr 1997; 16: 43-55.
32. Nakaya Y, Okita K, Suzuki K etal. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 2007; 23: 113-20.
33. Nakamura I, Ochiai K, Imai Y, Moriyasu F, Imawari M. Restoration of innate host defense responses by oral supplementation of branched-chain amino acids in decompensated cirrhotic patients. Hepatol Res 2007; 37: 1062-7.
34. Sugiyama K, Yu L, Nagasue N. Direct effect of branched-chain amino acids on the growth and metabolism of cultured human hepatocellular cells. Nutr Cancer 1998; 31: 62-8.
35. Saito Y, Saito H, Nakamura M etal. Effect of the molar ratio of branched-chain to aromatic amino acids on growth and albumin mRNA expression of human liver cancer cell lines in a serum-free medium. Nutr Cancer 2001; 39: 126-31.
36. Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 2011; 54: 1063-70. doi: 10.1002/hep.24412.
37. Poon RT, Yu W, Fan S, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther 2004; 19: 779-88.
38. Takeshita S, Ichikawa T, Nakao K etal. A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. Nutr Res 2009; 29: 89-93.
39. Kuroda H, Ushio A, Miyamoto Y etal. Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol 2010; 25: 1550-5.
40. Harima Y, Yamasaki T, Hamabe S etal. Effect of a late evening snack using branched-chain amino acid-enriched nutrients in patients undergoing hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res 2010; 40: 574-84.
41. Silva AM, Hider RC. Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. Biochim Biophys Acta 2009; 1794: 1449-58.
42. Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol 2004; 36: 2137-43.
43. Kawabata H, Yang R, Hirama T etal. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem 1999; 274: 20826-32.
44. Ikuta K, Zak O, Aisen P. Recycling, degradation and sensitivity to the synergistic anion of transferrin in the receptor-independent route of iron uptake by human hepatoma (HuH-7) cells. Int J Biochem Cell Biol 2004; 36: 340-52.
45. Shindo M, Torimoto Y, Saito H etal. Functional role of DMT1 in transferrin-independent iron uptake by human hepatocyte and hepatocellular carcinoma cell, HLF. Hepatol Res 2006; 35: 152-62.
46. Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc Natl Acad Sci U S A 2006; 103: 13612-17.
47. Oudit GY, Sun H, Trivieri MG etal. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9: 1187-94.
48. Miyazaki E, Kato J, Kobune M etal. Denatured H-ferritin subunit is a major constituent of haemosiderin in the liver of patients with iron overload. Gut 2002; 50: 413-19.
49. Um HD, Orenstein JM, Wahl SM. Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol 1996; 156: 3469-77.
50. Sakaida I, Kyle ME, Farber JL. Autophagic degradation of protein generates a pool of ferric iron required for the killing of cultured hepatocytes by an oxidative stress. Mol Pharmacol 1990; 37: 435-42.
51. Sakaida I, Thomas AP, Farber JL. Increases in cytosolic calcium ion concentration can be dissociated from the killing of cultured hepatocytes by tert-butyl hydroperoxide. J Biol Chem 1991; 266: 717-22.
52. Sakaida I, Hironaka K, Uchida K, Okita K. Iron chelator deferoxamine reduces preneoplastic lesions in liver induced by choline-deficient L-amino acid-defined diet in rats. Dig Dis Sci 1999; 44: 560-9.
53. Fujita N, Sugimoto R, Takeo M etal. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 2007; 13: 97-104.
54. Nagashima M, Kudo M, Chung H etal. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res 2006; 36: 288-93.
55. Nishina S, Hino K, Korenaga M etal. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226-38.
56. Kato J, Kobune M, Nakamura T etal. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001; 61: 8697-702.
57. Kato J, Miyanishi K, Kobune M etal. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007; 42: 830-6.
58. Asare GA, Kew MC, Mossanda KS, Paterson AC, Siziba K, Kahler-Venter CP. Effects of exogenous antioxidants on dietary iron overload. J Clin Biochem Nutr 2009; 44: 85-94.
59. Sakaida I, Kayano K, Wasaki S, Nagatomi A, Matsumura Y, Okita K. Protection against acetaminophen-induced liver injury in vivo by an iron chelator, deferoxamine. Scand J Gastroenterol 1995; 50: 61-7.
60. Jin H, Terai S, Sakaida I. The iron chelator deferoxamine causes activated hepatic stellate cells to become quiescent and to undergo apoptosis. J Gastroenterol 2007; 42: 475-84.
61. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007; 6: 1982-94.
62. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990; 50: 4929-30.
63. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011; 365: 576-8.
64. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010; 45: 794-807.
65. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-26.